Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Elubrixin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 known ✓ | P25025 | 20/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elubrixin SCHEMBL1562280 | 0.91 | CXCR2 (1.00) | CXCR2 | |
| Elubrixin SCHEMBL30515706 | 0.91 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL4162988 | 0.91 | CXCR2 (0.84) | CXCR2 | |
| Elubrixin SCHEMBL1741720 | 0.90 | CXCR2 (0.98) | CXCR2 | |
| SCHEMBL1568743 | 0.85 | CXCR2 (0.67) | CXCR2 | |
| SCHEMBL13629874 | 0.84 | CXCR2 (0.70) | CXCR2 | |
| SCHEMBL6564144 | 0.82 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL1562925 | 0.82 | CXCR2 (1.00) | CXCR2 | |
| Hydrochloric Acid SCHEMBL4355911 | 0.81 | CXCR2 (0.98) | CXCR2 | |
| SCHEMBL13096283 | 0.79 | CXCR2 (0.79) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | claimed |
| EP-2034832-B1 | IL-8 RECEPTOR ANTAGONIST | GLAXOSMITHKLINE LLC (US) | 2013-10-02 | — | — | EP | claimed |
| US-20100256157-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2010-10-07 | — | — | US | claimed |
| EP-2203432-A1 | METHOD OF TREATMENT | GlaxoSmithKline LLC (US) | 2010-07-07 | — | — | EP | claimed |
| US-20090281110-A1 | Method of Treatment | SMITHKLINE BEECHAM CORPORATION | 2009-11-12 | — | — | US | claimed |
| US-20090170871-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-02 | — | — | US | claimed |
| WO-2009039091-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-26 | — | — | WO | claimed |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12384792-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | TWELVE THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4585268-A2 | SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME | Twelve Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250171453-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-3350183-B1 | SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS INC (US) | 2025-04-02 | — | — | EP | disclosed |
| US-12152032-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-2490722-A2 | MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS | Otonomy, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049958-A2 | MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20100256157-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100021416-A1 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090297533-A1 | CONTROLLED RELEASE IMMUNOMODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090170871-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256157-A1 | METHOD OF TREATMENT | CFTR, CTH, TST | CXCR2 794/4885 |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | PRKCB, PRKCD, PRKCA | CXCR2 3008/4885 |
| US-12384792-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | PIK3CA, PIK3C2A, PIK3CD | CXCR2 2303/4885 |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | CXCR2 2874/4885 |
| US-20090281110-A1 | Method of Treatment | ESR2, CTH, SULT2A1 | CXCR2 2176/4885 |
| US-12152032-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | CXCR2 942/4885 |
| US-20100021416-A1 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, TLR3, STING1 | CXCR2 562/4885 |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | CXCR2 563/4885 |
| US-20250171453-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | CXCR2 942/4885 |
| US-20090297533-A1 | CONTROLLED RELEASE IMMUNOMODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, CD74, TSLP | CXCR2 1421/4885 |
| US-20090170871-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | CXCR2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.